Orphazyme to discuss NPC rejection with FDA in mid-October
Denmark-based biotech company Orphazyme has planned a meeting with the US Food and Drug Administration to discuss the rejection it received in June.
by christopher due karlsson, translated by catherine brett
Progress appears to have been made in Orphazyme's ongoing battle to get its key candidate, arimoclomal, approved as a treatment for Niemann-Pick Type C (NPC) in the US.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Orphazyme may face class action suit from US investors
For subscribers
Orphazyme expects to lay off 100 employees this year
For subscribers
.jpg&w=384&q=75)
